Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Melvin Mezue, a PhD student in the Department of Clinical Neurosciences, has been named UK's top black student at the annual Rare Rising Stars Award ceremony.

Melvin Mezue of St Hugh's College, who is studying neuroscience, won the 2013 Rare Rising Stars award for his achievements in academia and business.

Now in its fifth year, Rare Rising Stars showcases the achievements of the best black students in the UK. The judging panel included David Lammy MP, Trevor Phillips OBE, Jean Tomlin OBE, Tom Chigbo, Sam Gyimah MP, and Adrian Joseph, Director of Search Advertising at Google for Northern and Central Europe.

Mr Mezue is one of four Oxford students in the top ten. Named in fourth, fifth and sixth place respectively were Ify Aniebo, an MSc in Public Health at St Catherine’s College; Uchechukwu Ukachi, a Master’s student in Engineering, Economics and Management at St John’s College; and Ré Phillips, an MPhil in International Development at St Anthony's College. Olympic taekwondo bronze medallist Lutalo Muhammad also made the top ten.

Mr Mezue investigates the way that the brain processes pain, with the aim of developing new treatments for chronic pain syndromes. Some of his research has been exhibited at the Science Museum and featured on BBC's The One Show. He has also co-founded a youth-led media company, Streamline Empire Ltd, and was President of the Oxford University Africa Society.

Raphael Mokades, Managing Director of Rare, said: 'Melvin and the other stars have shown that there are brilliant, inspirational black young people out there who are making an enormous difference to society. Whether they’re found on stage, in a South African township or in the Universities of Oxford or Cambridge, our Stars have continued to defy stereotypes, push boundaries and shine brightly as high achievers and outstanding role models.'

Related news:

The Voice online

Oxford Mail

Similar stories

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.